German contrast media developer Insight Agents announced the European launch of two new generic contrast media products, one for x-ray and CT in Germany, and one for MRI in 22 European countries.
Magnegita 500 μmol/mL (gadopentetate dimeglumine) is intended for use in contrast-enhanced MRI of the whole body and central nervous system (CNS), as well as angiography (excluding coronary arteries). It is also indicated for myocardial perfusion studies under certain circumstances.
Iopamigita 300 mg Iod/mL (iopamidol) is a nonionic contrast medium for x-ray and CT imaging, including arteriography, angiography throughout the cardiovascular system, peripheral venography (phlebography), digital subtraction angiography, and urography, as well as CT head and body imaging for adults and pediatric patients.
Neither contrast agent is available in the U.S., and they have not yet been cleared by the U.S. Food and Drug Administration, according to the Heidelberg-based company.
Copyright © 2007 AuntMinnie.com
![Axial images from unenhanced calcium score cardiac CT (left) and curved planar reformation images from CT angiography (right) show that higher long-term exposure to air pollution is associated with greater coronary artery calcium and more obstructive coronary artery disease (CAD). Top row: Images in a 68-year-old male patient with higher 10-year mean ambient air pollution exposure (7.9 μg/m3 for particulate matter measuring ≤2.5 μm in diameter [PM2.5] and 17.4 parts per billion [ppb] for NO2) with extensive CAD (coronary artery calcium score [CACS] >1,000 and obstructive CAD [≥70% diameter stenosis]). Bottom row: Images in a 57-year-old female patient with lower 10-year mean ambient air pollution exposure (6.3 μg/m3 for PM2.5 and 4.6 ppb for NO2) with no CAD (CACS = 0 and no obstructive stenosis).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/06/hanneman.r6SMLzkezo.png?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
